Review of Sorrento Therapeutics (OTCMKTS:SRNEQ) and iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics ( NASDAQ:ITOS – Get Your Free Report ) and Sorrento Therapeutics ( OTCMKTS:SRNEQ – Get Your Free Report ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on their risk strength, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and risk

iTeos Therapeutics has a beta of 1.4, meaning its share price is 40% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.25, meaning its share price is 125 % more volatile than the S&P 500.

Earnings and Rating

This table compares iTeos Therapeutics and Sorrento Therapeutics’ gross revenue, earnings per share and valuation.

iTeos Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics.

Institutional and insider ownership

97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 12.5% ​​of iTeos Therapeutics shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a company will outperform the market over the long term.

Analyst ratings

This is a breakdown of recent valuations for iTeos Therapeutics and Sorrento Therapeutics, as reported by MarketBeat.

iTeos Therapeutics currently has a consensus target price of $30.50, indicating a potential upside of 104.15%. Given iTeos Therapeutics’ higher probable upside, research analysts plainly believe iTeos Therapeutics is more favorable than Sorrento Therapeutics.

return

This table compares iTeos Therapeutics and Sorrento Therapeutics’ net margins, return on equity and return on assets.

Summary

iTeos Therapeutics beats Sorrento Therapeutics on 6 of the 10 factors comparing the two stocks.

About iTeos Therapeutics

(Get a free report)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of immuno-oncology therapies for cancer patients. The company’s lead antibody product candidate, belrestotug, a TIGIT or T-cell immunoreceptor antagonist with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor or Fc?R to dendritic activation. cells, natural killer cells and macrophages and to promote antibody-dependent cellular cytotoxicity or ADCC activity. The product line also independently includes a next-generation A2AR antagonist that is in phase 1/2a clinical trials to overcome adenosine-mediated immunosuppression found in the tumor microenvironment; and EOS-984, a small molecule that targets equilibrated nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

About Sorrento Therapeutics

(Get a free report)

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, is developing a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapy by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody conjugate , as well as the bispecific antibody approach; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as amyloidosis and graft-versus-host disease. The company is developing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of advanced cancer pain and osteoarthritis; and ZTlido, a topical lidocaine system for the treatment of post-herpetic neuralgia. It is engaged in the development of SEMDEXA, an injectable viscous gel formulation, which is a phase III study for the treatment of sciatica, a back pain pathology; SP-103, an investigational non-aqueous lidocaine system in clinical development in chronic low back pain; and SP-104, a new low-dose delayed-release formulation of naltrexone hydrochloride for the treatment of fibromyalgia. Partner with SmartPharm Therapeutics Inc. to develop a vaccine with genetically encoded antibodies to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using Sofusa’s lymphatic drug delivery technology to deliver Ipilimumab to melanoma patients. The company was founded in 2006 and is headquartered in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., together with its affiliate, filed a voluntary petition for Chapter 11 reorganization in the US Bankruptcy Court for the Southern District of Texas. The plan was later approved as a Chapter 11 liquidation on November 30, 2023.

Get news and reviews for iTeos Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iTeos Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.